- Jul 2018
-
europepmc.org europepmc.org
-
On 2014 Sep 01, Matthew Katz commented:
This EORTC trial offers hope for better outcomes for glioblastoma, a very aggressive disease. Temozolomide as a therapy and MGMT methylation status as a key prognostic factor are key advances defined by this phase III trial. In the same issue, the MGMT data were published. Hegi ME, 2005
Five-year updated data were published in Lancet Oncol 2009 update. Stupp R, 2009
This comment, imported by Hypothesis from PubMed Commons, is licensed under CC BY.
-
- Feb 2018
-
europepmc.org europepmc.org
-
On 2014 Sep 01, Matthew Katz commented:
This EORTC trial offers hope for better outcomes for glioblastoma, a very aggressive disease. Temozolomide as a therapy and MGMT methylation status as a key prognostic factor are key advances defined by this phase III trial. In the same issue, the MGMT data were published. Hegi ME, 2005
Five-year updated data were published in Lancet Oncol 2009 update. Stupp R, 2009
This comment, imported by Hypothesis from PubMed Commons, is licensed under CC BY.
-